Skip to content

Comparison between different contrast media on Contrast-Induced Acute Kidney Injury in AMI patients undergoing primary percutaneous coronary intervention

Comparison of iodixanol and iohexol on Contrast-Induced Acute Kidney Injury in AMI patients undergoing primary percutaneous coronary intervention

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16010141
Enrollment
Unknown
Registered
2016-12-12
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-Induced Acute Kidney Injury

Interventions

iodixanol:iodixanol will be administered during PCI
iohexol:iohexol will be administered during PCI

Sponsors

Department of Cardiology, General Hospital of Guang Zhou Military Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Men or women aged >18 years; 2. Patients with Acute Myocardial Infarction presenting within 12 hours after the onset of symptoms (18 hours in case of cardiogenic shock,or within 24 hours after thrombolysis), who are scheduled to undergo primary PCI; 3. Patients who have signed and dated the written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients in pregnancy or lactation; 2. Long-term dialysis or severe renal dysfunction(CKD4-5); 3. Intra-arterial or intravenous administration of iodinated contrast medium from 7 days before to 72 hours after the administration of study drug; 4. Intake of any nephrotoxic medications 24 hours before or after the administration of study drug.

Design outcomes

Primary

MeasureTime frame
Incidence of CI-AKI;

Secondary

MeasureTime frame
MACE;proportion of patients with severe acute renal failure and dialysis;

Countries

China

Contacts

Public ContactXiang Dingcheng

Department of Cardiology, General Hospital of Guang Zhou Military Command

dcxiang@foxmail.com+86 13609008024

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026